
BOSTON and NEW YORK — Nov. 16, 2026 — STAT, the leading health and medicine news organization, and WireScreen, a China-focused risk intelligence platform, today launched the STAT China Biotech Index, powered by WireScreen, a new quarterly resource designed to help life sciences leaders understand China's rapidly evolving biotechnology sector.
The inaugural edition, China's Biotech Powerhouse 25, ranks 25 leading publicly traded Chinese companies focused on discovering and developing proprietary medicines. The ranking applies a methodology developed by STAT using company and market data compiled with WireScreen. It is intended to provide a consistent, evidence-based view of the companies driving China's emergence as a major source of drug innovation.
China has become an increasingly important force in global biotechnology, influencing drug pipelines, licensing strategies, investment decisions, and U.S. policy. The new index will give biotech and pharmaceutical executives, investors, business-development leaders, policymakers, and researchers a clearer way to follow that change.
"China's biotechnology industry is reshaping the global market for medicines, and our readers need a reliable way to understand the companies behind that shift," said Seth Harris, senior vice president of growth and subscriptions at STAT. "This collaboration brings together STAT's authoritative reporting and knowledge of the life sciences with WireScreen's deep expertise in Chinese companies and corporate data."
The index evaluates publicly traded companies whose core business is discovering and owning proprietary medicines for human use, and whose primary scientific and operating roots are in China. Eligible companies are listed in Hong Kong, Shanghai, Shenzhen, or New York (Nasdaq and the NYSE). The 25 largest qualifying companies are selected by market capitalization and then ranked using two equally weighted measures: market value and revenue.
Along with the rankings, the inaugural edition includes company profiles and an explanation of the methodology, placing the results in the context of the broader changes underway in global biotechnology.
"Making sense of China's corporate landscape is extraordinarily difficult, even for the most sophisticated global organizations," said David Barboza, co-founder and CEO of WireScreen. "By combining WireScreen's data and research capabilities with STAT's expertise in biotechnology and medicine, we can provide better insights for decision-makers tracking changes in China's fast-growing drug industry."
The STAT China Biotech Index is scheduled to be updated quarterly during its first year, allowing readers to track changes in the rankings and the companies' progress over time. The launch also expands STAT's coverage of China's growing role in drug development, dealmaking, and international life sciences policy.
The inaugural ranking and methodology are available at statnews.com/china-biotech-index-powerhouse-25 and thewirechina.com/2026/11/16/chinas-biotech-powerhouse. Registration is required, but access to the index is free.
STAT delivers trusted, tough-minded journalism on the business of making medicines, health technology, science, public health, hospitals, and insurance. Its award-winning newsroom provides indispensable reporting and analysis of the technologies, personalities, companies, and political forces transforming health and medicine.
WireScreen is a China-focused risk intelligence platform that helps organizations understand corporate ownership, business relationships, supply chains, and other connections within China's complex business landscape. Its platform draws on corporate filings, trade data, patents, procurement documents, and other primary sources to help users evaluate companies, investments, and business relationships. WireScreen is a division of The Wire Digital Inc., a New York-based news and data company.
WireScreen
Krassi Genov
Head of Marketing
krassi.genov@wirescreen.ai